

Lancor Scientific

04:15 27 Aug 2018

Tumour Trace: A revolution in cancer detection

Nottingham-based Tumour Trace has developed the OMIS cancer detection system.

OMIS stands for Opto-magnetic Imaging Spectroscopy and it was the brainchild of Professor Djuro Koruga, the company's chief scientific officer.

It is the physical embodiment of his research at the University of Belgrade and, put simply, the device detects the minute electromagnetic changes that occur in tissue as cancer emerges and develops.

A sample can be garnered using minimally invasive techniques and read-outs emerge in 'near' real-time (less than 30 seconds), while the technology itself is "cancer agnostic". That said, it is currently CE marked as a screening tool for cervical cancer.

READ: The our big picture overview of Lancor Scientific

WATCH: A tangible solution for cancer screening

Be aware there is a difference between a screening device and a diagnostic.

Screening is a pre-emptive process that sees tens of thousands of people annually assessed for the early signs of breast, cervical and prostate cancers.

It saves many lives but it isn't an exact science, with around a 60% strike rate. In other words, there are a lot of false positives.

OMIS is a far more reliable predictor. Its sensitivity is 84% and its specificity is 77%. That puts it right at the top end for screening.

READ: Blockchain is the Swiss Army knife of the information era

However, for it to be a proper diagnostic tool it needs to rival the gold standard in this arena - biopsy. So, the aim is to refine OMIS to the point where it provides the correct diagnosis around 97% of the time.

Clinical trials of the technology are set to take place in Germany, Austria and the UK, alongside retrospective analysis.

OMIS may struggle (initially at least) to supplant the current techniques used in the developed world, which is why the early adopters are likely to be in the emerging countries where screening is non-existent.

Share Information

Code: LANCO

Listing: PRIVATE-UK

Sector: Pharma & Biotech

Website: www.lancorscientific.com

Company Synopsis:

The Lancor Blockchain Platform (LBP)

The Lancor Blockchain Platform (LBP) blockchain architecture provides the opportunity for trusted, verifiable, and auditable data, adding a greater level of authenticity to any data generated within its infrastructure. Our blockchain implementation offers "potential solutions" to many of the issues raised by the WHO.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Lancor Scientific named herein, including the promotion by the Company of Lancor Scientific in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).